^
TNFRSF8 positive
HL
brentuximab vedotin
Sensitive
:
A1
No biomarker
HL
pembrolizumab
Sensitive
:
A1
No biomarker
HL
carmustine
Sensitive
:
A1
No biomarker
HL
nivolumab
Sensitive
:
A1
No biomarker
HL
R-CHOP
Sensitive
:
A2
No biomarker
HL
rituximab
Sensitive
:
A2
No biomarker
HL
R-CVP
Sensitive
:
A2
No biomarker
HL
brentuximab vedotin
Sensitive
:
A2
No biomarker
HL
bortezomib
Sensitive
:
A2
No biomarker
HL
everolimus
Sensitive
:
A2
No biomarker
HL
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
No biomarker
HL
bendamustine
Sensitive
:
A2
No biomarker
HL
nivolumab + brentuximab vedotin
Sensitive
:
A2
No biomarker
HL
lenalidomide
Sensitive
:
A2
No biomarker
HL
rituximab + bendamustine
Sensitive
:
A2
No biomarker
HL
GemOx
Sensitive
:
A2
No biomarker
HL
ICE
Sensitive
:
A2
No biomarker
HL
ESHAP
Sensitive
:
A2
No biomarker
HL
DHAP
Sensitive
:
A2
No biomarker
HL
R-ESHAP
Sensitive
:
A2
No biomarker
HL
MINE
Sensitive
:
A2
CHD8 mutation
HL
sintilimab
Resistant
:
C3
CELF2 mutation
HL
sintilimab
Resistant
:
C3
ABCC2 underexpression
HL
nivolumab + brentuximab vedotin
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our